Researcher: Gürses, Bengi
Name Variants
Gürses, Bengi
Email Address
Birth Date
24 results
Search Results
Now showing 1 - 10 of 24
Publication Metadata only The role of PSMA PET/CT in predicting downgrading in patients with Gleason score 4+4 prostate cancer in prostate biopsy(Springer, 2024) N/A; Aykanat, İbrahim Can; Kordan, Yakup; Seymen, Hülya; Köseoğlu, Ersin; Özkan, Arif; Esen, Barış; Tarım, Kayhan; Kulaç, İbrahim; Falay, Fikri Okan; Gürses, Bengi; Baydar, Dilek Ertoy; Canda, Abdullah Erdem; Balbay, Mevlana Derya; Demirkol, Mehmet Onur; Esen, Tarık; School of Medicine; Koç University HospitalBackground To investigate the predictable parameters associated with downgrading in patients with a Gleason score (GS) 8 (4+4) in prostate biopsy after radical prostatectomy. Methods We retrospectively analyzed 62 patients with a GS of 4+4 on prostate biopsy who underwent robotic radical prostatectomy between 2017 and 2022. Results 38 of 62 (61.2%) were downgraded. In multivariable logistic regression model, Ga-68 prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) SUV max was independent predictor of downgrading (OR 0.904; p = 0.011) and a Logistic Regression model was constructed using the following formula: Y = 1.465-0.95 (PSMA PET/CT SUV max). The model using this variable correctly predicted the downgrading in 72.6% of patients. The AUC for PSMA PET/CT SUV max was 0.709 the cut off being 8.8. A subgroup analysis was performed in 37 patients who had no other European Association of Urology (EAU) high risk features. 25 out of 37 (67.5%) were downgraded, and 21 of these 25 had organ confined disease. Low PSMA SUV max (<8.1) and percentage of GS 4+4 biopsy cores to cancer bearing cores (45.0%) were independently associated with downgrading to GS 7. Conclusion PSMA PET/CT can be used to predict downgrading in patients with GS 4+4 PCa. Patients with GS 4+4 disease, but no other EAU high risk features, low percentage of GS 4+4 biopsy cores to cancer bearing cores, and a low PSMA PET/CT SUV max are associated with a high likelihood of the cancer reclassification to intermediate risk group.Publication Metadata only Natural history of histologically benign PIRADS 4-5 lesions in multiparametric MRI: real-life experience in an academic center(Wiley, 2024) Madendere, Serdar; Kılıç, Mert; Zoroğlu, Hatice; Coşkun, Bilgen; Vural, Metin; Sarıkaya, Ahmet Furkan; Veznikli, Mert; Armutlu, Ayşe; Kulaç, İbrahim; Gürses, Bengi; Kiremit, Murat Can; Baydar, Dilek Ertoy; Canda, Abdullah Erdem; Balbay, Mevlana Derya; Kordan, Yakup; Esen, Tarık; School of Medicine; Koç University HospitalIntroductionThe follow-up findings of patients who underwent prostate biopsy for prostate image reporting and data system (PIRADS) 4 or 5 multiparametric magnetic resonance imaging (mpMRI) findings and had benign histology were retrospectively reviewed. MethodsThere were 190 biopsy-naive patients. Patients with at least 12 months of follow-up between 2012 and 2023 were evaluated. All MRIs were interpreted by two very experienced uroradiologists. Of the patients, 125 had either cognitive or software fusion MR-targeted biopsies with 4 + 8/10 cores. The remaining 65 patients had in-bore biopsies with 4-5 cores. Prostate-specific antigen (PSA) levels below 4 ng/mL were defined as PSA regression following biopsy. PIRADS 1-3 lesions on new MRI images were classified as MRI regression. ResultsMedian patient age and PSA were 62 (39-82) years and six (0.4-33) ng/mL, respectively, at the initial work-up. During a median follow-up period of 44 months, 37 (19.4%) patients were lost to follow-up. Of the remaining 153 patients, 82 (53.6%) had persistently high PSA. Among them, 72 (87.8%) had repeat mpMRI within 6-24 months which showed regressive findings (PIRADS 1-3) in 53 patients (73.6%) and PIRADS 4-5 index lesion persistence in 19 cases (26.4%). The latter group was recommended to have rebiopsy. Of these 19 patients, 16 underwent MRI-targeted rebiopsy. Prostate cancer was diagnosed in six (37.5%) patients and of these four (25%) were clinically significant (>Grade Group 1). Totally, clinically significant prostate cancer was detected in 4/153 (2.6%) patients followed up. ConclusionPatients should be warned against the relative relaxing effect of a negative biopsy after identification of PIRADS 4-5 index lesion. While PSA decrease was observed in many patients during follow-up, persistent MRI findings were present in nearly a quarter of patients with persistently high PSA. A rebiopsy is warranted in these patients, with significant prostate cancer diagnosed in a quarter of patients with rebiopsy.Publication Metadata only Intra-ampullary papillary tubular neoplasm (IAPN): clinicopathologic analysis of 72 cases highlights the distinctive characteristics(Elsevier Science Inc, 2023) Tarcan, Zeynep; Akar, Kadriye; Bagci, Pelin; Bozkurtlar, Emine; Ozkan, Hulya Sahin; Ozcan, Kerem; Balci, Serdar; Yilmaz, Serpil; Bilge, Orhan; Basturk, Olca; Esmer, Rohat; Saka, Burcu; Armutlu, Ayşe; Kapran, Yersu; Meriçöz, Çisel Aydın; Cengiz, Duygu; Gürses, Bengi; Alper, Emrah; Tellioğlu, Gürkan; Bozkurt, Emre; Adsay, Nazmi Volkan; School of Medicine; Koç University HospitalN/APublication Metadata only Metaplastic (centrally-necrotic demarcated) carcinomas of the pancreas immunohistochemically classify as basal type, further warranting their classification as a separate category (ICD-O:8575/3) as in the breast(Elsevier Science Inc, 2023) Bagci, Pelin; Pehlivanoglu, Burcin; Bozkurtlar, Emine; Reid, Michelle; Bilge, Orhan; Cheng, Jeanette; Luchini, Claudio; Scarpa, Aldo; Cengiz, Duygu; Meriçöz, Çisel Aydın; Esmer, Rohat; Saka, Burcu; Armutlu, Ayşe; Alper, Emrah; Tellioğlu, Gürkan; Gürses, Bengi; Adsay, Nazmi Volkan; School of Medicine; Koç University HospitalN/APublication Metadata only Sagittal (duct-centric) grossing of whipple specimens as a novel approach that combines the benefits of the axial and bivalving methods and provides more detailed documentation of anatomic variations and pathologic conditions: radiologic-pathologic correlative analysis of 61 cases(Elsevier Science Inc, 2023) Kurt, Ozgur; Kayim, Hatice Goksu; Bilge, Orhan; Basturk, Olca; Tezcan, Nuray; Cengiz, Duygu; Esmer, Rohat; Aktaş, Berk Kaan; Armutlu, Ayşe; Saka, Burcu; Kapran, Yersu; Karakaya, Afak Durur; Bozkurt, Emre; Tellioğlu, Gürkan; Alper, Emrah; Gürses, Bengi; School of Medicine; Koç University HospitalN/APublication Metadata only The pathologic characteristics at the primary resected tumor for pancreatic neuroendocrine tumors (pannets) that proved to have metastatic behavior(Elsevier Science Inc, 2023) Eren, Ozgur; Bagci, Pelin; Balci, Serdar; Sokmensuer, Cenk; Xue, Yue; Pehlivanoglu, Burcin; Reid, Michelle; Maithel, Shishir; Kooby, David; Sarmiento, Juan; Bilge, Orhan; Basturk, Olca; Bozkurt, Emre; Esmer, Rohat; Saka, Burcu; Armutlu, Ayşe; Kapran, Yersu; Gürses, Bengi; Tellioğlu, Gürkan; Adsay, Nazmi Volkan; School of Medicine; Koç University HospitalN/APublication Metadata only A distinctive stromal reaction as the herald of uncertain carcinoma foci in the peritoneal frozen sections of post-neoadjuvant gastric poorly cohesive /signet ring cell carcinomas(Elsevier Science Inc, 2023) Aktaş, Berk Kaan; Esmer, Rohat; Tezcan, Nuray; Taşkın, Orhun Çığ; Armutlu, Ayşe; Saka, Burcu; Kapran, Yersu; Gürses, Bengi; Rencüzoğulları, Ahmet; Özoran, Emre; Buğra, Dursun; Özcan, Gülnihal; Balık, Emre; Adsay, Nazmi Volkan; School of MedicineN/APublication Metadata only Kidney and liver fat accumulation: from imaging to clinical consequences(Springer Science and Business Media Deutschland Gmbh, 2023) Siriopol, Dimitrie; van Raalte, Daniel H.; Cozzolino, Mario; Yıldız, Abdullah Burak; Vehbi, Sezan; Çöpür, Sidar; Gürses, Bengi; Karakaya, Afak Durur; Hasbal, Nuri Barış; Çetin, Bahar Tekin; Akyıldız, Murat; Kanbay, Mehmet; School of MedicineBackground: Recent studies indicate that accumulation of adipose tissue in various organs such as liver and kidney may contribute to the pathophysiology of metabolic syndrome. We aim to investigate the association between kidney and liver adipose tissue accumulation, assessed by the magnetic resonance imaging (MRI) proton density fat fraction technique, along with its relation to clinical and biochemical parameters. Methods: We included 51 volunteers with phenotypical features of metabolic syndrome (mean age = 34 years, mean body-mass index = 26.4 kg/m2) in our study in which liver and kidney adipose tissue accumulation was assessed via MRI-proton density fat fraction along with multiple other clinical and biochemical parameters such as estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio, serum lipid profile, liver function tests and body-mass index (BMI). Results: Our results from the univariate linear regression analysis indicate that both the kidney and liver scores were positively correlated with markers such as BMI, urine albumin-to-creatinine ratio, triglycerides (p < 0.001) and negatively correlated with eGFR (p < 0.05). In multivariate analysis, urine albumin-to-creatinine ratio (p < 0.05), triglycerides (p < 0.01), eGFR (p < 0.05) and BMI (p < 0.001) were found to be independently associated with kidney and liver fat accumulation, respectively (R 2 = 0.64;R 2 = 0.89). There was also a positive correlation between kidney and liver fat accumulation. Conclusion: We have found a significant association between adipose tissue accumulation in liver and kidney and the parameters of metabolic syndrome. Moreover, the presence of a strong association between kidney and liver fat accumulation and kidney function parameters such as urine albumin-to-creatinine ratio and eGFR may be an indicator of the clinical significance of parenchymal fat accumulation. Graphical abstract: [Figure not available: see fulltext.]. © 2023, The Author(s) under exclusive licence to Italian Society of Nephrology.Publication Metadata only Can the Briganti 2019 nomogram be modified to predict lymph node metastasis risk in patients with prostate cancer detected with in-bore biopsy?(Wiley, 2024) Madendere, Serdar; Kılıç, Mert; Vural, Metin; Gürses, Bengi; Armutlu, Ayşe; Kulaç, İbrahim; Tarım, Kayhan; Esen, Barış; Aykanat, İbrahim Can; Veznikli, Mert; Canda, Abdullah Erdem; Balbay, Mevlana Derya; Baydar, Dilek Ertoy; Kordan, Yakup; Esen, Tarık; Koç University RMK Academy of Interventional Medicine, Education, and Simulation (RMK AIMES) / Koç Universitesi RMK İleri Düzey Girişimsel Tıp, Eğitim ve Simülasyon Merkezi (RMK AIMES); School of Medicine; Koç University HospitalObjectives: We aimed to modify the Briganti 2019 nomogram and to test whether it is valid for patients who were diagnosed with prostate cancer through in-bore prostate biopsies. Methods: Data for 204 patients with positive multiparametric prostate MRI and prostate cancer identified either by mpMRI-cognitive/software fusion or in-bore biopsy and who underwent robot-assisted radical prostatectomy and extended pelvic lymph node dissection between 2012 and 2023 were retrospectively analyzed. The Briganti 2019 nomogram was applied to the mpMRI-cognitive/software fusion biopsy group (142 patients) in the original form, and then, two modifications were tested for the targeted component. Original and modified scores were compared. These modifications were adapted for the in-bore biopsy group (62 patients). The final histopathologic stage was regarded as the gold standard. Results: Nodal metastases were identified in 18/142 (12.6%) of mpMRI-cognitive/software fusion biopsy patients and 8/62 (12.9%) of the in-bore biopsy patients. In the mpMRI-cognitive/software fusion biopsy group, tumor size/core size (%) of targeted biopsy cores and positive core percentage on systematic biopsy were significant parameters for lymph node metastasis based on univariate logistic regression analyses (p < 0.05). With the modifications of these parameters for the in-bore biopsy group, V1 modification of the Briganti 2019 nomogram provided 100% sensitivity and 31.5% specificity (AUC:0.627), while V2 modification provided 75% sensitivity and 46.3% specificity (AUC:0.645). Conclusions: Briganti 2019 nomogram may be modified by utilizing tumor size/core size (%) for targeted biopsy cores instead of positive core percentage on systematic biopsy or by not taking both parameters into consideration to detect node metastasis risk of patients diagnosed with in-bore biopsies.Publication Metadata only Multimodal assessment after total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer accurately predicts complete responders(Springer, 2023) Gürbüz, Bülent; Özoran, Emre; Özata, İbrahim Halil; Uymaz, Derya Salim; Omarov, Nail; Bozkurt, Emre; Tüfekçi, Tutku; Karahan, Salih Nafiz; Selçukbiricik, Fatih; Bölükbaşı, Yasemin; Taşkın, Orhun Çığ; Gürses, Bengi; Rencüzoğulları, Ahmet; Buğra, Dursun; Balık, Emre; School of Medicine; Koç University HospitalPurpose This study aimed to compare local regrowth rates after total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy (SNCRT) in locally advanced rectal cancer (LARC) patients that were strictly selected and assessed with a multimodal approach. Secondary outcomes were 4-year disease-free (DFS) and overall survival (OS) rates.Methods Locally advanced rectal cancer patients without distant metastases treated at Koc Healthcare Group between January 2014 and January 2021 were included. Patients were assessed for complete response with a combination of digital rectal exam, endoscopy, and magnetic resonance imaging with a dedicated rectum protocol. The systemic evaluation was performed with an upper abdomen MRI using intravenous hepatobiliary contrast agent and a thorax CT.Results Of the 270 patients with LARC, 182 fulfilled the inclusion criteria. Ninety-seven (53.3%) underwent TNT, while 85 (46.7%) underwent SNCRT. A cumulative combination of pathological and sustained clinical complete response was significantly higher in the TNT group than in the SNCRT (45.4% vs. 20.0%, p < 0.0001). After a median follow-up of 48 months, seven patients in the W & W group had regrowth [TNT: 4 (10.8%) vs. SNCRT: 3 (23.1%), p = 0.357]. Based on pathological examination, complete/near complete mesorectum rates (p = 1.000) and circumferential resection margin positivity rates (p = 1.000) were similar between the groups. The 4-year DFS and OS rates were comparable. The patients with clinical or pathological complete response had significantly longer overall survival (p = 0.017) regardless of the type of neoadjuvant treatment.Conclusions Multimodal assessment after TNT effectively detects complete responders, resulting in low local recurrence and increased cumulative complete response rates. However, these outcomes did not translate into a survival advantage.
- «
- 1 (current)
- 2
- 3
- »